New drug combo aims to tame acromegaly hormone levels

NCT ID NCT07037420

Terminated Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo injections for 15 weeks. The main goal is to see if the drug reduces IGF-1 levels, a key marker of disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALXN2420 (a growth hormone blocker)
What this could lead to: If it works, this could offer a new treatment option for people with acromegaly whose disease is not fully controlled by current therapy.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not lower hormone levels enough or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY

Contacts and locations

Locations

Research Site

Torrance, California, 90502, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Pisa, 56126, Italy
Research Site

Kaunas, LT50009, Lithuania
Research Site

Vilnius, 09112, Lithuania
Research Site

Bucharest, 011863, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.